Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 10Phase 1 9Phase 1/2 6Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Gastrointestinal Stromal Tumors 2Progressive Gastrointestinal Stromal Tumor 1Myeloproliferative Disorders 1Mastocytosis, Systemic 1Mastocytosis 1Mast Cell Activation Disorders 1Leukemia, Myeloid, Chronic-Phase 1Hematologic Neoplasms 1Breast Neoplasms 1Blast Crisis 1

Interventions

nilotinib 2flumatinib 2Dasatinib 2Thiotepa 1Radiotherapy 1Imatinib Mesylate 1Filgrastim 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Myeloid, Chronic-Phase × Imatinib Mesylate × Clear all
NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 4 Not yet recruiting
2,400 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡